Jounce Therapeutics - 48 Year Dividend Yield History | JNCE

Historical dividend payout and yield for Jounce Therapeutics (JNCE) since 1971. The current TTM dividend payout for Jounce Therapeutics (JNCE) as of March 22, 2019 is $0.00. The current dividend yield for Jounce Therapeutics as of March 22, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.198B $0.065B
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $46.886B 31.19
Takeda Pharmaceutical (TAK) Japan $32.716B 12.10
Grifols (GRFS) Spain $12.878B 15.61
Mannatechorporated (MTEX) United States $0.043B 0.00